Shanghai UniXell Biotechnology
PrivateLast Round
Series A
Apr 18, 2025
Total Funding Raised
$71.38M
Company Overview
Shanghai UniXell Biotechnology operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series A round in April 2025.
Shanghai UniXell Biotechnology is a biotechnology company that develops human pluripotent stem cell (hPSC) based cell therapies for neurodegenerative and rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shanghai UniXell Biotechnology Comparables
Compare Shanghai UniXell Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Oryon Cell Therapies | 88% | |
| XellSmart | 87% | |
| iRegene Therapeutics | 86% |
For institutional investors. Book with your work email.
Shanghai UniXell Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 18, 2025 | ||||
| Series A | Jul 12, 2024 | ||||
| Series A | Apr 4, 2024 | ||||
| Pre Seed | Mar 14, 2022 | ||||
| Angel | Aug 25, 2021 |
For institutional investors. Book with your work email.
Shanghai UniXell Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hillhouse Investment | Pre Seed |
| Guokejiahe Fund | Series A |
| TF Capital | Pre Seed |
| CAS Venture Capital | Series A |
| Jiangsu Ruihua Investment Holding Group | Pre Seed |
| Kunlun Capital | Series A |
| Tasly Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 18, 2025
$19.18M round with participation from Guokejiahe Fund and Kunlun Capital.
- Jul 12, 2024
$1.38M round led by The Chinese Academy of Sciences Venture Capital Management
For institutional investors. Book with your work email.
Shanghai UniXell Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Shanghai UniXell Biotechnology's valuation, stock price, and market status.
Is Shanghai UniXell Biotechnology a public or private company?
Shanghai UniXell Biotechnology is a private company.
What is the current stock price of Shanghai UniXell Biotechnology?
Shanghai UniXell Biotechnology is a private company, so its shares have no public market price. Caplight tracks Shanghai UniXell Biotechnology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Shanghai UniXell Biotechnology worth (valuation)?
Valuation information for Shanghai UniXell Biotechnology is not publicly available.
Can I buy Shanghai UniXell Biotechnology stock?
Shanghai UniXell Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Shanghai UniXell Biotechnology's last funding round?
Shanghai UniXell Biotechnology's most recent funding round was Series A on April 18, 2025.
Who are the main investors in Shanghai UniXell Biotechnology?
Key investors in Shanghai UniXell Biotechnology include Tasly Capital, Sherpa Healthcare Partners, CDH Investments.
Will Shanghai UniXell Biotechnology IPO soon?
No public IPO plans have been announced for Shanghai UniXell Biotechnology.
How can I track Shanghai UniXell Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades in Shanghai UniXell Biotechnology's shares on secondary markets.